Genmab — November 2018
-
Ja i cHL. I NHL er responsraterne ikke så høje. https://ash.confex.com/ash/2018/webprogram/Paper115986.html
-
This is the first report of the use of daratumumab in LCDD. This antibody yielded rapid and significant hematologic responses in five of six heavily pretreated patients with this disease, preventing renal progression. Daratumumab represents a promising option for these patients and larger, international studies are warranted.
-
-
-
Det er jeg Bulder.
-
Tak Bulder...Har svaret.
'
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind